류마티스 관절염 환자에서 질병활성도 측정지표간의 유의성 비교

Abstract

ABSTRACT

The comparison of disease activity indexes for rheumatoid arthritis in clinical use

By Jeong Yu-Jin Advisor : Prof. Kim Hyun-Sook, M.D, Ph.D. Department of Medicine, Graduate School of Chosun University

(Background) Management of rheumatoid arthritis (RA) has evolved as an increasing number. The development of new disease modifying antirheumatic drugs (DMARDs)-including biologic agents targeted againt specific components of the immune system- has required the availability of instruments that permit the assessment of disease activity and the response to therapy. The roles of both individual variables (eg, swollen joint counts and acute phase reactant measurements) and composite indices for simple disease activity assessment are considered, as are definitions of remission and criteria for clinically significant responses.

(Method) Sixty six patients diagnosed RA were included at Chosun University Hospital from September 2009 to March 2010. We have analyzed the swollen joint counts , tender joints, acute phase reactant measurements (Erythrocyte sedimentation rate(ESR). C-reactive protein(CRP)). Then We calculated Disease activity score 28(DAS 28), Simplified disease activity index(SDAI), Clinical disease activity index (CDAI).

(Result) Compared with DAS 28, SDAI, CDAI can reflect disease activity of RA. And that reach statistical significance. (p<.001, p<.001). Also SDAI, CDAI in patients who use biologic DMARDs can reflect disease activity of RA. And that reach statistical significance (p<.01, p<.01).

(Conclusion) Not only DAS 28 but also SDAI, CDAI are valid measures and have been shown to be suitable measures to apply in a control strategy for treating RA.